Idebenone at a dose of 120 mg per day for six
months was used in the treatment of 35 patients aged 60-86 years
with Alzheimer's-type dementia, mixed dementia, and memory
impairments not reaching the stage of dementia. Patients were
assessed on the basis of data from somatic, neurological, and
psychiatric investigations, as well as neuropsychological testing
and a series of psychometric and other scales and tests, before and
after treatment. Significant improvements in patients' conditions on
the MMSE were seen in patients with mild and moderate dementia.
Improvements in daily activities were obtained in 27% of patients.
Neuropsychological investigations demonstrated improvements in
short-term and long-term memory and attention, with improvements in
speech functions, performance of kinesthetic, spatial, and dynamic
praxis tests, and in visuospatial gnosis, thought, and writing. On
the CGI scale, positive treatment effects were obtained in 37% of
patients, while 48% of patients remained in a stable state.